Evaluation of Paclitaxel, Ifosfamide, and Cisplatin (TIP) Regimen on Penile Cancer in Adam Malik Medan: A Single Center 2 Years of Experience

Abstract

BACKGROUND: Penile tumour is a rare tumour in the genitourinary system, account for 0.4-0.6%. Although rare, patients are often unaware and come in late stage, so the use of chemotherapy agents is becoming crucial.
 AIM: This study was conducted to evaluate responses and overall survival rate of Paclitaxel, Ifosfamide, and Cisplatin (TIP) regimen in penile cancer with nodal involvement.
 METHODS: We included all medical records of penile squamous cell carcinoma patients associated with nodal involvement who acquired TIP regimen in Adam Malik Hospital between 2014 and 2016. We administered 175 mg/m2 of Paclitaxel on day 1, 1200 mg/m2 of Ifosfamide on days 1 to 3, and 25 mg/m2 of Cisplatin on days 1 to 3 as our standard TIP regimen. The regimen was re-administered every 21-28 days. Characteristics of the patient including age, history of circumcision, races, primary lesion of the tumour and TNM staging were noted. Adverse event, clinical responses, and overall survival were assessed and evaluated.
 RESULTS: We extracted data from 17 patients of penile cancer with nodal involvement who acquired TIP regimen with a mean age of 44.18 ± 11.13 years old from our medical records. Only 10 patients completed the full 4 cycles of the regimen. Four patients died before completion, two patients refused to continue the regimen, and 1 patient is still on the second cycle. Total penectomy was the most frequent procedure had taken, and clinical stage T4 and N3 was the most findings at initial diagnosis. There was no complete response noted. Six patients were noted as partial response, and 1 patient was noted as progressive disease. The Kaplan-Meier curve shows an overall 6 months (95% CI: 4.4-7.6 months) of survival with a median of follow-up time was 7 (1-11) months. In subgroup analysis, we found that the responder group has significantly better overall survival than the non-responder group (log-rank test, p = 0.004).
 CONCLUSION: Paclitaxel, Ifosfamide, and Cisplatin (TIP) regimen give significant clinical benefit in penile cancer with nodal involvement.

Neoadjuvant chemotherapy for patients with locally advanced penile cancer

“…Furthermore, the ORR and pCR rate were comparable in several studies that used TP for NAC. 16 23 25 28 …”

“…Several retrospective studies have currently reported the application of NAC for locally advanced penile cancers. 13 15 16 17 18 21 22 23 24 25 26 27 28 29 The efficacy and safety of NAC were assessed to achieve the most up-to-date evidence and explore the optimal chemotherapy regimen.…”

Systemtherapie des Peniskarzinoms – neue Konzepte? Neue Erfolge?

“…Bei relativ hoher Toxizität erhielten nur 10/17 die geplanten 4 Zyklen. Es gab partielles Ansprechen in 6/17 Fällen, das Gesamtüberleben lag bei nur 6 Monaten [28]. Das TIP-Regime wurde trotzdem aufgrund der Empfehlung des NCCN der Standard in den USA [29].…”